Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 89.5% in May

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 1,948 shares, a decrease of 89.5% from the May 14th total of 18,505 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 324,828 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Down 1.5%

Provectus Biopharmaceuticals stock traded down $0.00 during midday trading on Wednesday, reaching $0.07. 18,990 shares of the company were exchanged, compared to its average volume of 268,193. The firm’s 50-day simple moving average is $0.06 and its 200-day simple moving average is $0.06. Provectus Biopharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.